IP Library Granted Patent US 10,533,047
Granted Patent B2
US 10,533,047 · App. 16/104,610 · Granted Jan 14, 2020

Anti-tenascin C antibodies and uses thereof

Inventors: Kim Suzanne Midwood (Buckinghamshire, GB); Philip Antony Bland-Ward (London, GB); Nigel Burns (London, GB); Patrick John Hextall (Cambridge, GB); Susan Rebecca Aungier (Oxford, GB)
Assignee: NASCIENT LIMITED
C07K16/18A61K39/3955C07K14/78G01N33/6893A61K2039/505C07K2317/33C07K2317/55C07K2317/56C07K2317/565C07K2317/567C07K2317/76C07K2317/92C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,533,047
App. No.
16/104,610
Granted
Jan 14, 2020
Kind
B2
Abstract

There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies.

Claims (3)

1. An anti-fibrinogen-like globe (FBG) domain of tenascin-C antibody or antigen-binding fragment thereof comprising a VH region and a VL region, wherein the VH region comprises SEQ ID NO: 37 and wherein the VL region comprises RASQYIQGFLN (SEQ ID NO: 5) for CDRL1, DASNLET (SEQ ID NO: 13) for CDRL2, and QQSYSTPQT (SEQ ID NO: 14) for CDRL3.

2. A composition comprising an antibody or antigen-binding fragment of claim 1 and a pharmaceutically acceptable carrier, excipient and/or diluent.

3. A method of treating rheumatoid arthritis comprising administering to a subject an effective amount of an antibody or antigen-binding fragment according to claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2021
From: NASCIENT LIMITED
To: STERLING IP LIMITED
Reel/Frame 055800/0382 →
Priority Claims (1)
GB 1414021.4 · Aug 7, 2014 · national
Continuity (2)
Continuation 15501979
Related Publication 20190055306A1 · Feb 21, 2019